Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Post procedural complication? 123 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 123 reports of Post procedural complication have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.2% of all adverse event reports for NATALIZUMAB.

123
Reports of Post procedural complication with NATALIZUMAB
0.2%
of all NATALIZUMAB reports
5
Deaths
96
Hospitalizations

How Dangerous Is Post procedural complication From NATALIZUMAB?

Of the 123 reports, 5 (4.1%) resulted in death, 96 (78.0%) required hospitalization, and 1 (0.8%) were considered life-threatening.

Is Post procedural complication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 123 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Post procedural complication?

ADALIMUMAB (2,494) ETANERCEPT (318) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (244) UPADACITINIB (241) RISANKIZUMAB-RZAA (232) INFLIXIMAB (217) METHOTREXATE (188) TREPROSTINIL (174) HUMAN IMMUNOGLOBULIN G (159) PREDNISONE (157)

Which NATALIZUMAB Alternatives Have Lower Post procedural complication Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Post procedural complication Reports All Drugs Causing Post procedural complication NATALIZUMAB Demographics